{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-25-000009","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.140921+00:00","generated_at":"2026-05-21T14:08:31.456061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SELLAS Q1 net loss $5.8M; cash $28.4M; reports positive OS in Phase 2 SLS009 AML trial","bullets":["Net loss of $5.8M ($0.07 per share) for Q1 2025 vs $9.6M ($0.21) in Q1 2024.","Cash and cash equivalents $28.4M as of March 31, 2025; plus $4.0M from warrant exercises in April 2025.","Phase 2 SLS009 in r/r AML: mOS 8.9 mo (AML-MRC) and 8.8 mo (venetoclax-resistant), beating historic 2.5 mo.","Phase 3 REGAL (GPS) interim analysis supports continuation; final analysis expected 2025.","Closed $25M registered direct offering in Jan 2025; net proceeds for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-25-000009","json":"https://secwatch.observer/filing/0001390478-25-000009.json","markdown":"https://secwatch.observer/filing/0001390478-25-000009.md","text":"https://secwatch.observer/filing/0001390478-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/0001390478-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/sls-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:08:31.456061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}